LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment ...
Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage ...
Irreversible electroporation using the NanoKnife System provided effective focal therapy option for intermediate-risk prostate cancer, with mostly favorable oncologic and functional outcomes. For ...
AngioDynamics ANGO recently announced that the FDA has approved its IDE application to initiate the RELIEF study, which will evaluate the irreversible electroporation (IRE) technology delivered by the ...
“The Palmetto GBA final LCD advances patient access to IRE as a recognized treatment option for appropriately selected patients,” said Juan Carlos Serna, AngioDynamics Senior Vice President of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results